Everand Logo

Welcome to Everand!

  • STAT

    AstraZeneca lung cancer immunotherapy trial failure sends shares plunging

    by Adam Feuerstein Jul 27, 2017 2 minutes
    Source: Kirsty Wigglesworth/AP

    A highly anticipated clinical trial combining two immunotherapy drugs failed to delay tumor growth in patients with newly diagnosed lung cancer, sending AstraZeneca sharply lower Thursday.

    The negative results from the so-called MYSTIC study are a stinging setback to AstraZeneca’s ambition to leapfrog over

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min readChemistry
    STAT+: Pharmalittle: We’re Reading About Fake Studies, AbbVie Investing In Psychedelics, And More
    Fake studies have flooded publishers of top scientific journals,. leading to thousands of retractions and millions of dollars in lost revenue.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About FDA Dithering On Pharma Patents, WHO Pandemic Talks, And More
    When it comes to a crucial controversy over patents for drug-and-device combination products, the FDA has been MIA.
    STAT1 min read
    Opinion: STAT+: How AI Can Help Satisfy FDA’s Drug, Device Diversity Requirements
    To meet the Food and Drug Omnibus Reform Act, companies must rethink their current clinical trial strategies. Including AI and machine learning approaches can help.

    Related Books & Audiobooks